The results were presented at the recent Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, a meeting jointly sponsored by the NCI, AACR, and EORTC.
A second investigational drug in the isocitrate dehydrogenase (IDH) inhibitor class has demonstrated activity in acute myeloid leukemia (AML), a small clinical study showed.
Seven of 14 patients with relapsed or refractory AML had objective responses to treatment with AG-120, an orally available inhibitor of IDH1. The clinical activity included four complete responses.
The drug has been well tolerated during the ongoing phase I trial to identify the optimal dose for continued clinical evaluation, Daniel Pollyea, MD, assistant professor of medicine at the University of Colorado in Denver, reported at the Symposium on Molecular Targets and Cancer Therapeutics in Barcelona.
Earlier this year, another small phase I study showed activity with the IDH2 inhibitor AG-221, which resulted in objective responses in six of seven patients with relapsed or refractory AML.
Link to the report on Medpage Today: http://bit.ly/1I9dX4R
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More